M&A
ANI Pharmaceuticals Offers $560 Million for Sweden’s Egetis
ANI Pharmaceuticals Inc. launched a recommended public cash offer for Egetis Therapeutics AB, valuing the Swedish rare-disease company at about $560 million and adding…
Archive
rare disease
M&A
AstraZeneca Makes Roughly $10 Billion Offer for Rhythm
AstraZeneca PLC has offered to buy Rhythm Pharmaceuticals Inc. for about $10 billion, according to people familiar with the matter, in a bid to…